GSK drops 1% in premarket trading after CDC updates RSV vaccination guidance

On Wednesday, the CDC updated its recommendation for the use of Respiratory Syncytial Virus vaccines in people ages 60 and older. For this upcoming respiratory virus season, CDC recommends: Everyone ages 75 and older receive the RSV vaccine. People ages 60-74 who are at increased risk of severe RSV, meaning they have certain chronic medical conditions, such as lung or heart disease, or they live in nursing homes, receive the RSV vaccine. This recommendation is for adults who did not get an RSV vaccine last year. The RSV vaccine is not currently an annual vaccine, meaning people do not need to get a dose every RSV season. The Fly notes that GSK‘s Arexvy vaccine received FDA approval to expand its use for 50-59 year-olds earlier this month. Shares of GSK are down 1% in premarket trading.